Cost-effectiveness of elbasvir/grazoprevir for the treatment of chronic hepatitis c: a systematic review

HIGHLIGHTS

  • who: Lei Ke and Ruxu You from the Department of Pharmacy, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Wuhan, China have published the research work: Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review, in the Journal: (JOURNAL) of 31/Dec/2020
  • what: Since EBR/GZR entered the market, more and more studies focused on its efficacy, safety, and costeffectiveness, which have provided massive evidence for a deeper understanding. Data Synthesis To summarize and evaluate the aims, methods, settings, and results of the studies . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?